A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra; When Used In Routine Medical Practice (LIBERATE)
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms LIBERATE
- Sponsors Biogen
- 28 Jul 2021 Results (n=4646) evaluating safety data and patient reported physical and psychological impact of MS while taking Prolonged-release fampridine, published in the CNS Drugs
- 26 May 2020 Results from this study, were presented at the 6th Congress of the European Academy of Neurology.
- 04 Jun 2019 Status changed from active, no longer recruiting to completed.